NO20062135L - Fenylderivater som PPAR-agonister - Google Patents
Fenylderivater som PPAR-agonisterInfo
- Publication number
- NO20062135L NO20062135L NO20062135A NO20062135A NO20062135L NO 20062135 L NO20062135 L NO 20062135L NO 20062135 A NO20062135 A NO 20062135A NO 20062135 A NO20062135 A NO 20062135A NO 20062135 L NO20062135 L NO 20062135L
- Authority
- NO
- Norway
- Prior art keywords
- ppar agonists
- phenyl derivatives
- compounds
- relates
- agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Foreliggende oppfinnelse angår forbindelser med formelen og X1, X2, Y1 til Y4, R1 til R13 og m og n er som definert i beskrivelsen, og alle enantiomerer og farmasøytisk akseptable salter og/eller estere derav. Oppfinnelsen angår videre farmasøytiske preparater inneholdende slike forbindelser, en fremgangsmåte for fremstilling av dem, og anvendelse av dem for behandling og/eller forebygging av sykdommer som blir modulert av PPAR8- og/eller PPARa-agonister.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03104081 | 2003-11-05 | ||
EP04100759 | 2004-02-26 | ||
PCT/EP2004/012217 WO2005049573A1 (en) | 2003-11-05 | 2004-10-28 | Phenyl derivatives as ppar agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062135L true NO20062135L (no) | 2006-05-24 |
Family
ID=34553652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062135A NO20062135L (no) | 2003-11-05 | 2006-05-12 | Fenylderivater som PPAR-agonister |
Country Status (18)
Country | Link |
---|---|
US (1) | US7115611B2 (no) |
EP (2) | EP1682508A1 (no) |
JP (2) | JP4745244B2 (no) |
KR (2) | KR20080042188A (no) |
CN (1) | CN1875002B (no) |
AR (1) | AR046924A1 (no) |
AU (1) | AU2004291262C1 (no) |
BR (1) | BRPI0416283A (no) |
CA (1) | CA2543249C (no) |
HK (1) | HK1098156A1 (no) |
IL (1) | IL175139A (no) |
MX (1) | MXPA06004641A (no) |
MY (1) | MY138906A (no) |
NO (1) | NO20062135L (no) |
NZ (1) | NZ546444A (no) |
RU (1) | RU2374230C2 (no) |
TW (1) | TWI259179B (no) |
WO (1) | WO2005049573A1 (no) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
CN1875002B (zh) * | 2003-11-05 | 2011-08-03 | 霍夫曼-拉罗奇有限公司 | 作为ppar激动剂的苯基衍生物 |
ATE544765T1 (de) * | 2003-12-22 | 2012-02-15 | Leuven K U Res & Dev | Imidazoä4,5-cüpyridinverbindungen und verfahren zur antiviralen behandlung |
CA2560111A1 (en) * | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
EP1745033A4 (en) * | 2004-05-08 | 2009-08-26 | Neurogen Corp | 2-ARYLPYRIMIDINES DISUBSTITUTED IN 4,5 |
PE20060315A1 (es) * | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
ES2324794T3 (es) * | 2004-12-21 | 2009-08-14 | Gilead Sciences Inc | Imidazo(4,5-c)pyridine componente y metodo de tratamiento antiviral. |
US7300931B2 (en) | 2004-12-28 | 2007-11-27 | Kinex Pharmaceuticals, Llc | Compositions for treating cell proliferation disorders |
US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
MX2007009343A (es) * | 2005-02-15 | 2007-09-21 | Hoffmann La Roche | Derivados de amida como activadores de receptor activado por proliferador de peroxisomas. |
CA2598934A1 (en) * | 2005-02-25 | 2006-08-31 | Takeda Pharmaceutical Company Limited | Pyridyl acetic acid compounds |
DE602006009804D1 (de) * | 2005-06-02 | 2009-11-26 | Hoffmann La Roche | Piperidin-4-yl-amidderivate und ihre verwendung als antagonisten des sst-rezeptors vom subtyp 5 |
WO2007001150A2 (en) * | 2005-06-27 | 2007-01-04 | Jae-Kwan Hwang | Method for preventing and treating conditions mediated by ppar using macelignan |
US7429605B2 (en) | 2005-08-04 | 2008-09-30 | Hoffmann-La Roche Inc. | Phenylpyridine derivatives |
EP1940767A2 (en) * | 2005-09-07 | 2008-07-09 | Plexxikon, Inc. | Pparactive compounds |
JP5564251B2 (ja) | 2006-06-29 | 2014-07-30 | キネックス ファーマシューティカルズ, エルエルシー | キナーゼカスケードを調節するためのビアリール組成物および方法 |
CN102617571B (zh) * | 2006-07-07 | 2015-06-10 | 吉里德科学公司 | 新的哒嗪化合物及其用途 |
KR100951653B1 (ko) * | 2006-12-02 | 2010-04-07 | 재단법인서울대학교산학협력재단 | 퍼록시솜 증식자 활성화 수용체 리간드 아릴 화합물 및이들 화합물의 용도 |
US7935697B2 (en) | 2006-12-28 | 2011-05-03 | Kinex Pharmaceuticals, Llc | Compositions for modulating a kinase cascade and methods of use thereof |
UA99466C2 (en) * | 2007-07-06 | 2012-08-27 | Гилиад Сайенсиз, Инк. | Crystalline pyridazine compound |
JP5291708B2 (ja) * | 2007-07-25 | 2013-09-18 | 中国人民解放軍軍事医学科学院毒物薬物研究所 | アリールピリミジン誘導体、その製造方法、及び、その使用 |
DE102007042754A1 (de) | 2007-09-07 | 2009-03-12 | Bayer Healthcare Ag | Substituierte 6-Phenylnikotinsäuren und ihre Verwendung |
DE102007061757A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung |
WO2009153721A1 (en) | 2008-06-18 | 2009-12-23 | Pfizer Limited | Nicotinamide derivatives |
EP2755944B1 (en) | 2011-09-16 | 2017-06-14 | Sanofi | Biarylderivatives,their preparation and their therapeutic application |
AP2014007805A0 (en) | 2011-12-28 | 2014-07-31 | Cytokinetics Inc The Regents Of The University Of California | Substituted benzaldehyde compounds and methods fortheir use in increasing tissue oxygenation |
US9012450B2 (en) | 2011-12-28 | 2015-04-21 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
US9181186B2 (en) * | 2012-02-13 | 2015-11-10 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
CN109999040A (zh) | 2012-08-30 | 2019-07-12 | 阿西纳斯公司 | 蛋白质酪氨酸激酶调节剂 |
MX2015011769A (es) | 2013-03-15 | 2016-06-02 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina. |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
SG10201802911RA (en) | 2013-03-15 | 2018-05-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
EP2970308B1 (en) | 2013-03-15 | 2021-07-14 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CA2902874C (en) * | 2013-03-15 | 2021-04-20 | Global Blood Therapeutics, Inc. | Substituted pyridinyl-6-methoxy-benzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
PT3102208T (pt) | 2014-02-07 | 2021-04-05 | Global Blood Therapeutics Inc | Polimorfos cristalinos da base livre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3 il)metoxi)benzaldeído |
CN107257790A (zh) | 2014-12-18 | 2017-10-17 | 拜耳医药股份有限公司 | 取代的吡啶基‑环烷基‑羧酸、包含它们的组合物及其医学用途 |
BR112018011272A2 (pt) | 2015-12-04 | 2018-11-21 | Global Blood Therapeutics Inc | regimes de dosagem para 2-hidróxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metóxi)benzaldeído |
CN106831437B (zh) * | 2016-02-03 | 2019-06-21 | 华中师范大学 | 含硝基乙烯基的酯类化合物及其制备方法和应用 |
TWI752307B (zh) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | 新穎化合物及製造化合物之方法 |
TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
US11891382B2 (en) | 2017-04-26 | 2024-02-06 | Basilea Pharmaceutica International AG | Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof |
EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
CN111100033B (zh) * | 2019-12-25 | 2022-07-26 | 合肥工业大学 | 一种酰胺晶体化合物的合成方法及用途 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3781367A (en) | 1970-01-15 | 1973-12-25 | Continental Oil Co | Preparation of 4-mercaptophenols |
TW257757B (no) | 1993-03-03 | 1995-09-21 | Boehringer Mannheim Gmbh | |
TW403748B (en) | 1994-11-02 | 2000-09-01 | Takeda Chemical Industries Ltd | An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same |
ATE262334T1 (de) * | 1996-02-02 | 2004-04-15 | Merck & Co Inc | Antidiabetisches mittel |
US5905068A (en) | 1996-09-24 | 1999-05-18 | Abbott Laboratories | Retroviral protease inhibiting compounds |
NZ520752A (en) | 2000-02-16 | 2004-03-26 | Smithkline Beecham P | Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors |
JP2001261654A (ja) * | 2000-03-21 | 2001-09-26 | Mitsui Chemicals Inc | キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
AU2001277056B2 (en) * | 2000-07-25 | 2005-09-29 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
DE60129712T2 (de) * | 2000-08-23 | 2008-07-03 | Eli Lilly And Co., Indianapolis | Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten |
GB0111523D0 (en) | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
KR100654516B1 (ko) | 2001-05-15 | 2006-12-05 | 에프. 호프만-라 로슈 아게 | 당뇨병 치료에서 ppar-알파 및 -감마 활성제로서사용하기 위한 카복실산 치환된 옥사졸 유도체 |
GB0113231D0 (en) | 2001-05-31 | 2001-07-25 | Glaxo Group Ltd | Chemical compounds |
JP2003171275A (ja) * | 2001-12-11 | 2003-06-17 | Sumitomo Pharmaceut Co Ltd | PPARδアゴニスト |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
JP2003292439A (ja) * | 2002-02-04 | 2003-10-15 | Sumitomo Pharmaceut Co Ltd | 新規ピロール誘導体からなるppar活性化剤 |
ES2290439T3 (es) | 2002-02-25 | 2008-02-16 | Eli Lilly And Company | Moduladores del receptor activado del proliferador de peroxisomas. |
JP4383177B2 (ja) * | 2002-03-01 | 2009-12-16 | スミスクライン ビーチャム コーポレーション | hPPAR活性化剤 |
US6875780B2 (en) * | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
JPWO2004007439A1 (ja) | 2002-07-10 | 2005-11-10 | 住友製薬株式会社 | ビアリール誘導体 |
CN1875002B (zh) * | 2003-11-05 | 2011-08-03 | 霍夫曼-拉罗奇有限公司 | 作为ppar激动剂的苯基衍生物 |
-
2004
- 2004-10-28 CN CN2004800322739A patent/CN1875002B/zh not_active Expired - Fee Related
- 2004-10-28 KR KR1020087010674A patent/KR20080042188A/ko not_active Application Discontinuation
- 2004-10-28 WO PCT/EP2004/012217 patent/WO2005049573A1/en active Application Filing
- 2004-10-28 JP JP2006538711A patent/JP4745244B2/ja not_active Expired - Fee Related
- 2004-10-28 KR KR1020067008742A patent/KR100847976B1/ko not_active IP Right Cessation
- 2004-10-28 EP EP04790987A patent/EP1682508A1/en not_active Withdrawn
- 2004-10-28 BR BRPI0416283-8A patent/BRPI0416283A/pt not_active IP Right Cessation
- 2004-10-28 EP EP20110152150 patent/EP2314576A1/en not_active Withdrawn
- 2004-10-28 CA CA2543249A patent/CA2543249C/en not_active Expired - Fee Related
- 2004-10-28 NZ NZ546444A patent/NZ546444A/en not_active IP Right Cessation
- 2004-10-28 RU RU2006119510/04A patent/RU2374230C2/ru not_active IP Right Cessation
- 2004-10-28 AU AU2004291262A patent/AU2004291262C1/en not_active Ceased
- 2004-10-28 MX MXPA06004641A patent/MXPA06004641A/es active IP Right Grant
- 2004-10-29 US US10/978,155 patent/US7115611B2/en not_active Expired - Fee Related
- 2004-11-03 MY MYPI20044550A patent/MY138906A/en unknown
- 2004-11-03 AR ARP040104043A patent/AR046924A1/es not_active Application Discontinuation
- 2004-11-04 TW TW093133654A patent/TWI259179B/zh not_active IP Right Cessation
-
2006
- 2006-04-24 IL IL175139A patent/IL175139A/en not_active IP Right Cessation
- 2006-05-12 NO NO20062135A patent/NO20062135L/no not_active Application Discontinuation
-
2007
- 2007-06-01 HK HK07105814.6A patent/HK1098156A1/xx not_active IP Right Cessation
-
2010
- 2010-12-17 JP JP2010281960A patent/JP2011093913A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TW200524870A (en) | 2005-08-01 |
EP1682508A1 (en) | 2006-07-26 |
MY138906A (en) | 2009-08-28 |
AU2004291262A1 (en) | 2005-06-02 |
CA2543249C (en) | 2012-08-07 |
US20050096337A1 (en) | 2005-05-05 |
NZ546444A (en) | 2009-09-25 |
RU2374230C2 (ru) | 2009-11-27 |
US7115611B2 (en) | 2006-10-03 |
JP4745244B2 (ja) | 2011-08-10 |
IL175139A (en) | 2011-10-31 |
BRPI0416283A (pt) | 2007-01-23 |
CN1875002B (zh) | 2011-08-03 |
RU2006119510A (ru) | 2007-12-27 |
EP2314576A1 (en) | 2011-04-27 |
JP2007509999A (ja) | 2007-04-19 |
AU2004291262C1 (en) | 2011-08-11 |
IL175139A0 (en) | 2006-09-05 |
HK1098156A1 (en) | 2007-07-13 |
JP2011093913A (ja) | 2011-05-12 |
TWI259179B (en) | 2006-08-01 |
AR046924A1 (es) | 2006-01-04 |
CN1875002A (zh) | 2006-12-06 |
AU2004291262B2 (en) | 2011-04-14 |
KR100847976B1 (ko) | 2008-07-22 |
WO2005049573A1 (en) | 2005-06-02 |
CA2543249A1 (en) | 2005-06-02 |
KR20060086373A (ko) | 2006-07-31 |
MXPA06004641A (es) | 2006-06-27 |
KR20080042188A (ko) | 2008-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062135L (no) | Fenylderivater som PPAR-agonister | |
NO20074592L (no) | Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister | |
NO20076197L (no) | Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander | |
NO20065880L (no) | 3-Amino-l-arylpropylindoler som monoamin-gjenopptagelsesinhibitor | |
NO20074703L (no) | Antibakterielle piperidinderivater | |
NO20083434L (no) | Benzamid- og heteroarenderivater | |
NO20076254L (no) | Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander | |
NO20061363L (no) | Pyrazolo- og imidazo- pyrimidinderivater | |
NO20070339L (no) | 1-aza-bicyklo[3 3.1]nonaner | |
NO20050016L (no) | Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen | |
NO20084382L (no) | Sykloalkylaminosyrederivater og farmasoytiske sammensetninger derav | |
NO20081315L (no) | Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser | |
TW200616979A (en) | Non-nucleoside reverse transcriptase inhibitors | |
NO20076195L (no) | Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer | |
NO20062591L (no) | Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet | |
NO20076138L (no) | Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander | |
NO20071137L (no) | Nye piperidinderivater for behandling av depresjon | |
NO20062583L (no) | Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet | |
NO20082124L (no) | Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom | |
NO20085218L (no) | Nye pyridinanaloger | |
NO20073831L (no) | Medikamenter for behandling eller forebygging av fibrotiske sykdommer | |
NO20084872L (no) | 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig | |
NO20071140L (no) | Nye piperidinderivater som histamin H3 reseptorligander for behandling av depresjon | |
NO20090327L (no) | Nye forbindelser 384 | |
NO20076137L (no) | Nye 2-azetidinonderivater og deres anvendelse som kolestrolabsorpsjonsinhibitorer for behandling av hyperlipidemi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |